Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 8INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 13Other solid neoplasm 6Gynecologic 6Genitourinary 6Gastrointestinal 4Tumor-Agnostic 3Thoracic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Classical hematology 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × talazoparib × Tumor-Agnostic × Clear all
NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT04635631 2023-10-10

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Pfizer

Phase 1 Completed
15 enrolled 38 charts
Tumor-Agnostic

Neoplasms

NCT02921919 2022-08-24

Open-Label Extension and Safety Study of Talazoparib

Pfizer

Phase 2 Completed
120 enrolled 16 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡